Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Sana Biotechnology, Inc.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades.  Sana is building differentiated capabilities across the spectrum of cell and gene therapy. 
 
Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body.  We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders.
 
Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Over 8 million people worldwide are currently living with type 1 diabetes. At Sana, we’re advancing our hypoimmune platform for the potential treatment of this and other serious diseases. 

Check out The Economist article below highlighting promising preclinical diabetes data using our hypoimmune technology that were recently published in Cell Stem Cell.

https://lnkd.in/gRcYJtY9

Cancer prevention awareness is a key step towards a healthier future. Together, let's inspire change, promote healthy lifestyles, and drive advancements in cancer innovation to prevent and treat cancer. 

Learn more about cancer prevention here: https://lnkd.in/gT2vd6hZ

#CancerPrevention #BiotechInnovation #Cellengineering #CellTherapy

We are excited to share the publication of preclinical diabetes data in Cell Stem Cell. 
 
Published data demonstrate that transplantation of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells provided lasting glucose control, enabling the achievement of exogenous insulin independence without immunosuppression in a diabetic non-human primate (NHP). 
 
These data underscore the diverse and vast potential of the hypoimmune platform to transform the diabetes treatment landscape and beyond. 
 
Read more here: https://lnkd.in/g589pFsJ

Today we announced the closing of an upsized $189M public offering. 
 
We would like to recognize the tremendous support from healthcare investors, as well as the significant interest from scientific and healthcare communities, as we collectively work to change the possible for patients. 

Read more here: https://lnkd.in/gmX_ZVnV

At Sana, we recognize first-hand the vital role women play in driving innovation and shaping the future of science and medicine. 

We are committed to continuing to break barriers, inspire the next generation, and build a more inclusive and diverse scientific community. 

#WomenInScience #GirlsInScience #BiotechInnovation #STEMdiversity

Sana welcomes the Year of the Wood Dragon, a revered symbol in Chinese culture embodying growth, prosperity, and good fortune. 

We Look forward to a year filled with creativity, innovation, and abundant opportunities. #LunarNewYear

At Sana, our focus on changing the possible for patients through engineered cells is matched by our commitment to bring awareness to cancer prevention and early detection. 

Join us in fostering awareness, driving innovation, and uniting against cancer. Together, we can make strides in both treatment and prevention. 
 
#WorldCancerDay #CellTherapy #CancerPrevention #EarlyDetection

Sana will be honoring Black History Month throughout the month of February through various events within our community. 

The Sana Pledge is a commitment to ending inequality for all, and a meaningful part of our effort is directed toward countering racism and supporting the Black community.

"The future never just happened. It was created." -- Mae Jemison

#BlackHistoryMonth

We are honored for another feature in BioSpace’s annual Hotbed Maps, representing the most thriving life science regions across the country. With three primary office locations, Sana will be featured in the #BioForest, #BiotechBay, and #Genetown maps. 

In each of our locations, employees are relentless in discovering therapies that shift the possible for patients. 

Learn more about Sana, our culture, and open positions here: https://sana.com/join-us/

#hiring #jobsatSana

Today we memorialize the millions of lives lost and honor those who survived the acts of the Holocaust. We must stand united against hatred and intolerance, ensuring such atrocities never happen again.
 
#HolocaustRemembranceDay

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	289K -		2.25M -	2.22M 1.51%	2.86M 28.75%	4.11M 43.79%
accumulated other comprehensive income loss		26K -	30K 15.38%	-1.37M 4,653.33%	-4.33M 216.76%	-60K 98.61%
cash and cash equivalents	30.63M -	80.03M 161.28%	412.00M 414.80%	253.03M 38.58%	176.76M 30.14%	137.35M 22.30%
cash and short term investments	30.63M -	138.98M 353.74%	412.00M 196.44%	746.88M 81.28%	434.01M 41.89%	209.03M 51.84%
common stock		1K -	2K 100%	18K 800%	19K 5.56%	20K 5.26%
deferred revenue				31.48M -
deferred revenue non current
deferrred tax liabilities non current
goodwill		140.63M -	140.63M 0%	140.63M 0%	140.63M 0%	140.63M 0%
goodwill and intangible assets		199.82M -	199.82M 0%	199.82M 0%	199.82M 0%	199.82M 0%
intangible assets		59.20M -	59.20M 0%	59.20M 0%	59.20M 0%	59.20M 0%
inventory
long term debt		46.36M -	68.20M 47.11%	101.78M 49.25%	95.86M 5.82%	90.90M 5.17%
long term investments			33.73M -	195.88M 480.72%	10.05M 94.87%
net debt	-30.63M -	-31.82M 3.89%	-340.09M 968.68%	-142.09M 58.22%	-68.51M 51.78%	-33.25M 51.46%
net receivables
other assets
other current assets	1.97M -	5.28M 168.62%	6.20M 17.46%	7.11M 14.54%	14.37M 102.31%	4.49M 68.78%
other current liabilities	1.50M -	17.98M 1,101.94%	25.49M 41.74%	56.38M 121.23%	96.25M 70.72%	47.18M 50.98%
other liabilities						1 -
other non current assets	1.15M -	2.30M 99.57%	2.33M 1.48%	13.82M 492.33%	9.01M 34.82%	6.37M 29.28%
other non current liabilities	45.74M -	492.05M 975.85%	1.05B 113.76%	199.89M 81.00%	116.04M 41.95%	122.41M 5.48%
othertotal stockholders equity	59K -	1.56M 2,540.68%	-844.68M 54,315.73%	385.80M 145.67%	1.56B 303.95%	1.63B 4.31%
preferred stock			852.90M -	1.13B 32.42%
property plant equipment net	585K -	69.31M 11,748.55%	109.94M 58.62%	161.78M 47.15%	159.40M 1.47%	145.59M 8.66%
retained earnings	-13.25M -	-144.13M 988.00%	-429.43M 197.95%	-785.36M 82.88%	-1.05B 34.31%	-1.34B 26.85%
short term debt		1.85M -	3.71M 100.87%	9.16M 146.74%	12.39M 35.31%	13.20M 6.47%
short term investments		58.95M -	253.46M 329.94%	297.97M 17.56%	247.20M 17.04%	71.68M 71.00%
tax assets
tax payables
total assets	34.33M -	415.70M 1,110.78%	730.30M 75.68%	1.13B 54.65%	822.72M 27.15%	565.30M 31.29%
total current assets	32.60M -	144.26M 342.58%	384.47M 166.50%	558.10M 45.16%	444.44M 20.37%	213.51M 51.96%
total current liabilities	1.78M -	19.83M 1,010.87%	31.45M 58.61%	99.23M 215.52%	111.50M 12.36%	64.49M 42.17%
total debt		48.21M -	71.91M 49.17%	110.94M 54.28%	108.25M 2.42%	104.10M 3.84%
total investments		58.95M -	287.19M 387.16%	493.85M 71.96%	257.25M 47.91%	71.68M 72.14%
total liabilities	47.52M -	558.24M 1,074.72%	1.15B 106.27%	400.90M 65.18%	323.40M 19.33%	277.79M 14.10%
total liabilities and stockholders equity	34.33M -	415.70M 1,110.78%	730.30M 75.68%	1.13B 54.65%	822.72M 27.15%	565.30M 31.29%
total non current assets	1.74M -	271.44M 15,526.66%	345.83M 27.41%	571.31M 65.20%	378.28M 33.79%	351.78M 7.01%
total non current liabilities	45.74M -	538.41M 1,077.21%	1.12B 108.02%	301.67M 73.07%	211.90M 29.76%	213.31M 0.66%
total stockholders equity	-13.19M -	-142.54M 980.85%	-421.18M 195.48%	728.50M 272.97%	499.31M 31.46%	287.51M 42.42%

NASDAQ:SANA

Sana Biotechnology, Inc.

Last Close

6.05

26/07 20:00

Market Cap

1.15B

Beta: 0.62

Volume Today

1.34M

Avg: 1.19M

PE Ratio

−4.34

PFCF: −4.09

Preview